(Reuters) – The following is a roundup of some of the latest scientific studies on the new coronavirus and efforts to find treatments and vaccines for COVID-19, the disease caused by the virus. New questions about inhibitor COVID-19 efficacy A new study raises fresh questions about the effectiveness of Gilead …
Read More »
(Reuters) – The U.S. Food and Drug Administration was able to update its emergency use authorization for Gilead Sciences Inc’s (GILD.O) brakesivir of drugs to admit patients admitted to hospital with moderate COVID-19, despite mixed test results, the company’s top study said on Friday. FILE PHOTO: An ampoule of Ebola …
Read More »
CHICAGO / NEW YORK (Reuters) – Approximately one-fifth of the 11,000 people enrolled in a 30,000-volunteer U.S. trial of a Pfizer COVID-19 vaccine (PFE.N) and German partner BioNTech (22UAy.F) are Black as Latino, groups among the hardest hit by the coronavirus virus pandemic, said a top Pfizer executive. PHILO PHOTO: …
Read More »
FILE PHOTO: A man walks past a sign outside Pfizer headquarters in the source of Manhattan in New York City, New York, USA, July 22, 2020. REUTERS / Carlo Allegri / File Photo (Reuters) – Shares of Pfizer Inc and US-listed shares of partner BioNTech SE rose on Friday after …
Read More »
(Reuters) – A US government program that compensates people who say they are harmed by an emergency vaccine has paid out on less than 10% of claims, raising questions about whether the process should be used to deal with any side effects from a coronavirus shot to sue, according to …
Read More »